Now that Pfizer has asked the FDA to approve its COVID-19 vaccine for kids aged 5 to 11, what might the rollout for this age group look like?
Pfizer/BioNTech Says Booster Dose Is 95.6% Effective in Phase 3 Trial
Wibbitz Top Stories
Pfizer/BioNTech , Says Booster Dose Is , 95.6% Effective in Phase 3 Trial.
On October 21, Pfizer/BioNTech said that a booster..
